ARTICLE I DEFINITIONSAsset Purchase Agreement • January 18th, 2005 • Synta Pharmaceuticals Corp • Massachusetts
NON-QUALIFIED STOCK OPTION AGREEMENT _____ SHARES OF COMMON STOCK, NO. $.0001 PAR VALUE PER SHARE SYNTA PHARMACEUTICALS CORP. As of _________ (the "Grant Date"), Synta Pharmaceuticals Corp. (the "Company"), a Delaware corporation, grants to...Non-Qualified Stock Option Agreement • April 22nd, 2005 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
ARTICLE I DEFINITIONSAsset Purchase Agreement • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
Exhibit 10.7 91 HARTWELL AVENUE LEXINGTON, MASSACHUSETTS Lease Dated January 13, 2005 THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building...Synta Pharmaceuticals Corp • November 22nd, 2006 • Pharmaceutical preparations • Massachusetts
INCENTIVE STOCK OPTION AGREEMENT _____ SHARES OF COMMON STOCK, NO. $.0001 PAR VALUE PER SHARE SYNTA PHARMACEUTICALS CORP. As of _________ (the "Grant Date"), Synta Pharmaceuticals Corp. (the "Company"), a Delaware corporation, grants to...Incentive Stock Option Agreement • April 22nd, 2005 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
22,000,000 Shares Synta Pharmaceuticals Corp. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 1st, 2015 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
representative, heir, beneficiary or an immediate family member or (iv) as distributions to members, partners or stockholders of the undersigned; provided, however, that in any such case under clauses (i), (ii), (iii) or (iv) above, it shall be a condition to such transfer that:
Exhibit 10.5 DUFFY HARTWELL LIMITED PARTNERSHIP COMMERCIAL LEASE 1. PARTIES: DUFFY HARTWELL LIMITED PARTNERSHIP, a Massachusetts limited partnership located at 411 Waverley Oaks Rd. Waltham MA, LESSOR, which expression shall include its successors and...Synta Pharmaceuticals Corp • November 22nd, 2006 • Pharmaceutical preparations
FORM OF ISO AGREEMENT INCENTIVE STOCK OPTION AGREEMENT ______ SHARES OF COMMON STOCK, NO. _____ $.0001 PAR VALUE PER SHARE SYNTA PHARMACEUTICALS CORP. As of _______ (the "Grant Date"), Synta Pharmaceuticals Corp. (the "Company"), a Delaware...Synta Pharmaceuticals Corp • January 23rd, 2007 • Pharmaceutical preparations • Delaware
MASTER LEASE AGREEMENT (QUASI) DATED AS OF NOVEMBER 10, 2004 ("AGREEMENT")Master Lease Agreement • January 4th, 2007 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
MADRIGAL PHARMACEUTICALS, INC. 1,200,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • December 12th, 2019 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Certain stockholders named in Schedule II hereto (the “Selling Stockholders”) of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,200,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 180,000 additional shares (the “Optional Shares”) of common stock, $0.0001 par value, of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares” of the Company. In the event only one underwriter is listed in Schedule 1 hereto, any references in this Agreement to the “Underwriters” shall be deemed to refer to the sole underwriter in the singular form listed in such Schedule 1.
Underwriting AgreementUnderwriting Agreement • December 21st, 2017 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,506,025 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 225,904 additional shares (the “Optional Shares”) of common stock, $0.0001 par value (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
SECOND AMENDMENT TO THE AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • February 5th, 2007 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLERSStock Exchange Agreement • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
ARTICLE III REPRESENTATIONS AND WARRANTIES OF STOCKHOLDERSAgreement of Merger • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
5,555,556 Shares of Common Stock par value $0.0001 SYNTA PHARMACEUTICALS CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • January 8th, 2010 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
MADRIGAL PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • June 1st, 2021 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Madrigal Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
EXHIBIT 10.24 January 27, 2006 Matthew Sherman [ADDRESS] Dear Matthew: The purpose of this letter agreement is to set forth our mutual understanding and agreement with respect to your separation from employment with Synta Pharmaceuticals Corp.. (the...Synta Pharmaceuticals Corp • December 1st, 2006 • Pharmaceutical preparations
FORM OF NQ OPTION AGREEMENT NON-QUALIFIED STOCK OPTION AGREEMENT _____ SHARES OF COMMON STOCK, NO. _____ $.0001 PAR VALUE PER SHARE SYNTA PHARMACEUTICALS CORP. As of _________ (the "Grant Date"), Synta Pharmaceuticals Corp. (the "Company"), a Delaware...Option Agreement • January 23rd, 2007 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
Exhibit 10.22 AGREEMENT AND RELEASE AGREEMENT AND RELEASE dated this 14th day of January, 2005, by and between Dr. Lan Bo Chen ("DR. CHEN") and Synta Pharmaceutical Corp. (the "COMPANY"). Dr. Chen and the Company may be referred to jointly as "THE...Agreement and Release • November 22nd, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
FIRST AMENDMENT TO THE AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTRights Agreement • November 22nd, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
April 18, 2005 Lan Bo Chen, Ph.D. [ADDRESS] Re: CONSULTING AGREEMENT -------------------- Dear Lan Bo: This letter is to confirm our understanding with respect to (i) your continued service to Synta Pharmaceuticals Corp. (the "Company") as a...Consulting Agreement • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 8th, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of August 7, 2023 by and between Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
INDENTURE DATED AS OF , 20 BETWEEN MADRIGAL PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in SeriesIndenture • June 1st, 2021 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS INDENTURE, dated as of , 20 , between MADRIGAL PHARMACEUTICALS, INC., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), and , as trustee (herein called the “Trustee”).
COMMON STOCK PURCHASE AGREEMENT Dated as of October 4, 2010 by and between SYNTA PHARMACEUTICALS CORP. and AZIMUTH OPPORTUNITY LTD.Common Stock Purchase Agreement • October 5th, 2010 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 4th day of October 2010 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Synta Pharmaceuticals Corp., a corporation organized and existing under the laws of the State of Delaware (the “Company”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in Annex A hereto.
MADRIGAL PHARMACEUTICALS, INC. 1,248,098 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 2,048,098 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 2nd, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations
Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) (i) an aggregate of 1,248,098 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”), and (ii) warrants of the Company to purchase 2,048,098 shares of Common Stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants” and, together with the Firm Shares, the “Firm Securities”). As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to 494,429 additional shares of Common Stock (the “Optional Shares”). The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called t
EXHIBIT 10.2(d) FORM OF NQ OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS NON- QUALIFIED STOCK OPTION AGREEMENT _____ SHARES OF COMMON STOCK, NO. _____ $.0001 PAR VALUE PER SHARE SYNTA PHARMACEUTICALS CORP. As of _________ (the "Grant Date"), Synta...Synta Pharmaceuticals Corp • January 23rd, 2007 • Pharmaceutical preparations • Delaware
RECITALSIndemnification Agreement • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
Exhibit 10.13 Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 April 18, 2005 Safi R. Bahcall, Ph.D. [ADDRESS] Dear Safi: This letter agreement is to confirm our understanding with you with respect to your employment as President and...Synta Pharmaceuticals Corp • December 1st, 2006 • Pharmaceutical preparations • Massachusetts
NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • September 11th, 2023 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
INCENTIVE STOCK OPTION AGREEMENT SHARES OF COMMON STOCK, $.0001 PAR VALUE PER SHAREIncentive Stock Option Agreement • March 31st, 2017 • Madrigal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
RECITALSInvestor Rights Agreement • December 1st, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 5th, 2010 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT, dated as of September 30, 2010 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is among GENERAL ELECTRIC CAPITAL CORPORATION (“GECC”), in its capacity as agent for Lenders (as defined below) (together with its successors and assigns in such capacity, “Agent”), the financial institutions who are or hereafter become parties to this Agreement as lenders (together with GECC, collectively the “Lenders”, and each individually, a “Lender”), SYNTA PHARMACEUTICALS CORP., a Delaware corporation (“Borrower”), and the other entities or persons, if any, who are or hereafter become parties to this Agreement as guarantors (each a “Guarantor” and collectively, the “Guarantors”, and together with Borrower, each a “Loan Party” and collectively, “Loan Parties”).
Common StockUnderwriting Agreement • February 5th, 2007 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
Exhibit 10.4 300,000 SHARES OF COMMON STOCK GRANT DATE: MAY 27, 2004 SYNTA PHARMACEUTICALS CORP. NON-QUALIFIED STOCK OPTION AGREEMENT SYNTA PHARMACEUTICALS CORP., a Delaware corporation (the "Company"), grants to KEITH R. GOLLUST (the "Optionee"), as...Qualified Stock Option Agreement • November 22nd, 2006 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
SEVERANCE AND CHANGE OF CONTROL AGREEMENTSeverance and Change of Control Agreement • December 4th, 2014 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Massachusetts
This Agreement (the “Agreement”) is entered into as of the 3rd day of December, 2014 by and between Synta Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Chen Schor (the “Executive”).
